omniture
logo
Search
沈阳三生制药有限责任公司 S BIO.PHARM.GROUP I
Media Room

Latest News

rss

3S Bio Announces 2026 Interim Results: Innovation-Driven, Win-Win Collaboration, and Sustainable Growth

SHANGHAI, Aug. 21, 2026 /PRNewswire/ -- 3S Bio (01530.HK) today announced its interim results for t...

2026-08-21 15:39 3456

Sunshine Guojian Releases 2026 Interim Report:

Innovation-driven, Steady Advancement SHANGHAI, Aug. 21, 2026 /PRNewswire/ -- Today, Sunshine Guoji...

2026-08-21 08:00 3242

3SBio Announces 2025 Annual Results: Dual Engines of Innovative R&D and Global Collaboration Propel Revenue Past RMB 10 Billion Milestone

SHANGHAI, March 31, 2026 /PRNewswire/ -- 3SBio Inc. (01530.HK ) today released i...

2026-03-31 20:13 7448

3SBio announces 2023 interim results, with revenue growing over 20% year on year and pipeline value constantly enhanced

HONG KONG, Aug. 25, 2023 /PRNewswire/ -- Chinese leading biopharmaceutical company 3SBio (01530.HK)...

2023-08-25 10:06 6134
3SBio announces 2023 interim results, with revenue growing over 20% year on year and pipeline value constantly enhanced

3SBio announces 2022 annual results, with revenue rising 7.5% year on year and normalized net profit attributable to parents jumping 25.2%

HONG KONG, March 22, 2023 /PRNewswire/ -- Chinese leading biopharmaceutical company 3SBio (01530.HK...

2023-03-22 11:15 5138
3SBio announces 2022 annual results, with revenue rising 7.5% year on year and normalized net profit attributable to parents jumping 25.2%

HanBio Therapeutics Announces the Completion of a US$40 Million Series A Financing Led by OrbiMed and Hankang Capital

SHANGHAI, Jan. 28, 2022 /PRNewswire/ -- HanBio Therapeutics ("HanBio"), a biotechnology company com...

2022-01-29 11:37 8079

3SBio announces 2021 interim results, with strong growth in core businesses and significant progress in clinical development

HONG KONG, Aug. 26, 2021 /PRNewswire/ -- Chinese leading biopharmaceutical company 3SBio (01530.HK)...

2021-08-26 22:09 6936